紫杉醇联合卡培他滨一线治疗晚期胃癌的临床观察

目的　观察紫杉醇联合卡培他滨一线治疗晚期胃癌的疗效和毒副反应。方法　晚期胃癌患者２０例，给予紫杉醇８０ｍｇ／ｍ２静脉滴注，第１、８天；卡培他滨１０００ｍｇ／ｍ２，分早晚各口服１次，第１～１４天；２１天为１周期。每２周期评价疗效。结果　１９例可评价疗效，获ＣＲ１例，ＰＲ７例，总有效率（ＲＲ）为４２.１％。中位无进展生存期和总生存期分别为４.８个月和９.７个月，１年生存率为３６.８％。主要的毒副反应为血液学毒性、脱发和手足综合症。结论　紫杉醇联合卡培他滨治疗晚期胃癌安全、有效，值得临床进一步应用。

Clinical study of paclitaxel combined with capecitabine as first-line treatment for advanced gastric cancer

Objective To observe the clinical effect and side effects of paclitaxel combined with capecitabine as first-line treatment for patients with advanced gastric cancer.Methods Twenty patients with advanced gastric cancer were enrolled in the study and administrated with intravenous paclitaxel（80mg/m2,d1and d8）and oral capecitabin（1000mg/m2,bid,d1-d14）in a 21-day cycle regimen.Results Nineteen patients were evaluable for efficacy and toxicity.One patient achieved complete responses,7 patients achieved partial responses,and the overall response rate was 42.1%.The median progression-free survial and overall survival were 4.8 and 9.7 months,repectively,with the 1-year survival rate of 36.8%.The major side effects were hematotoxicity,alopecia and hand-foot syndrome.Conclusion The combination of paclitaxel and capecitabine was an effective and well-tolerated chemotherapy regimen for advanced gastric cancer.